Compare Stocks: SYRE, RVMD, BIIB, and ALNY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$174.00 -25.1%	$237.78	$172.31 ▼ $479.79	$31.10B	0.28	1.41 million shs	11.80 million shs
BIIB Biogen	$249.65 +2.3%	$226.29	$138.00 ▼ $258.78	$36.06B	0.09	1.35 million shs	1.16 million shs
RVMD Revolution Medicines	$190.27 +0.8%	$199.63	$56.66 ▼ $224.31	$40.45B	1.4	2.01 million shs	1.32 million shs
SYRE Spyre Therapeutics	$98.96 -0.8%	$90.28	$21.15 ▼ $110.18	$10.17B	3.1	1.40 million shs	567,635 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+2.47%	+3.24%	-8.99%	+13.10%	-51.17%
BIIB Biogen	-3.43%	+1.27%	+6.72%	+17.37%	+63.65%
RVMD Revolution Medicines	+1.34%	-2.86%	-6.45%	-1.80%	+224.43%
SYRE Spyre Therapeutics	+0.72%	+7.32%	+16.27%	-1.72%	+304.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$174.00 -25.1%	$237.78	$172.31 ▼ $479.79	$31.10B	0.28	1.41 million shs	11.80 million shs
BIIB Biogen	$249.65 +2.3%	$226.29	$138.00 ▼ $258.78	$36.06B	0.09	1.35 million shs	1.16 million shs
RVMD Revolution Medicines	$190.27 +0.8%	$199.63	$56.66 ▼ $224.31	$40.45B	1.4	2.01 million shs	1.32 million shs
SYRE Spyre Therapeutics	$98.96 -0.8%	$90.28	$21.15 ▼ $110.18	$10.17B	3.1	1.40 million shs	567,635 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+2.47%	+3.24%	-8.99%	+13.10%	-51.17%
BIIB Biogen	-3.43%	+1.27%	+6.72%	+17.37%	+63.65%
RVMD Revolution Medicines	+1.34%	-2.86%	-6.45%	-1.80%	+224.43%
SYRE Spyre Therapeutics	+0.72%	+7.32%	+16.27%	-1.72%	+304.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.81	Moderate Buy	$355.10	104.08% Upside
BIIB Biogen	2.67	Moderate Buy	$251.00	0.54% Upside
RVMD Revolution Medicines	2.92	Moderate Buy	$242.90	27.66% Upside
SYRE Spyre Therapeutics	2.94	Moderate Buy	$110.40	11.56% Upside

Current Analyst Ratings Breakdown

Latest SYRE, RVMD, BIIB, and ALNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/29/2026	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$256.00 ➝ $272.00
10/29/2026	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$212.00 ➝ $225.00
10/29/2026	BIIB Biogen	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$270.00 ➝ $300.00
10/29/2026	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$357.00 ➝ $243.00
10/29/2026	ALNY Alnylam Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$225.00
10/29/2026	BIIB Biogen	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$248.00 ➝ $272.00
10/29/2026	BIIB Biogen	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$231.00 ➝ $238.00
10/29/2026	BIIB Biogen	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$250.00 ➝ $260.00
10/29/2026	BIIB Biogen	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$235.00 ➝ $260.00
10/29/2026	BIIB Biogen	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Buy	$280.00
10/29/2026	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$256.00 ➝ $290.00

(Data available from 10/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.80B	4.85	$2.17 per share	80.12	$5.97 per share	29.15
BIIB Biogen	$10.03B	3.68	$22.53 per share	11.08	$124.45 per share	2.01
RVMD Revolution Medicines	$11.58M	3,521.80	N/A	N/A	$8.44 per share	22.54
SYRE Spyre Therapeutics	$890K	11,331.48	N/A	N/A	$7.21 per share	13.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	32.34	18.83	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	44.19	15.53	2.99	8.32%	11.18%	6.88%	N/A
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest SYRE, RVMD, BIIB, and ALNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	RVMD Revolution Medicines	-$2.35	N/A	N/A	N/A	$25.58 million	N/A
11/3/2026	Q3 2026	SYRE Spyre Therapeutics	-$0.7807	N/A	N/A	N/A	N/A	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.66	$16.26	+$14.60	$15.72	$1.43 billion	$1.46 billion
10/28/2026	Q3 2026	BIIB Biogen	$1.99	$2.62	+$0.63	-$0.14	$2.63 billion	$2.80 billion
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
RVMD Revolution Medicines	0.40	11.38	11.38
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
RVMD Revolution Medicines	94.34%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
RVMD Revolution Medicines	7.60%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
RVMD Revolution Medicines	883	214.34 million	198.05 million	Optionable
SYRE Spyre Therapeutics	112	101.91 million	85.92 million	Optionable

SYRE, RVMD, BIIB, and ALNY Headlines

Recent News About These Companies

Spyre Therapeutics (SYRE) Projected to Release Quarterly Earnings on Tuesday

October 27 at 8:40 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Share Price Breaks Above Fifty Day Moving Average - Should You Sell?

October 27 at 4:59 AM | marketbeat.com

Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview

October 23, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Given Buy Rating at BTIG Research

October 19, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 7.1% - What's Next?

October 19, 2026 | marketbeat.com

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

October 18, 2026 | globenewswire.com

Assenagon Asset Management S.A. Makes New $53.35 Million Investment in Spyre Therapeutics, Inc. $SYRE

October 18, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by UBS Group

October 14, 2026 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Has Consensus Target Price of $109.71 According to Analysts

October 10, 2026 | marketbeat.com

Spyre Therapeutics Announces $350 Million Public Stock Offering Priced at $85 Per Share

October 9, 2026 | kalkinemedia.comK

Spyre Therapeutics (NASDAQ:SYRE) Stock Jumps 7.3% - Here's What Happened

October 9, 2026 | marketbeat.com

Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering

October 8, 2026 | finance.yahoo.com

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - October 5, 2026

October 6, 2026 | biospace.comB

Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market

October 6, 2026 | finance.yahoo.com

Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell

October 6, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Falls 12.7% - Should You Sell?

October 6, 2026 | marketbeat.com

Spyre Therapeutics Prices $350 Mln Public Offering Of Shares

October 6, 2026 | rttnews.com

Spyre Therapeutics prices $350M public offering at $85 per share

October 6, 2026 | msn.com

Spyre Therapeutics Commences Public Offering of Common Stock

October 5, 2026 | finance.yahoo.com

Spyre Therapeutics stock falls on public offering launch

October 5, 2026 | finance.yahoo.com

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

October 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, RVMD, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$174.00 -58.40 (-25.13%)

Closing price 04:00 PM Eastern

Extended Trading

$176.90 +2.90 (+1.67%)

As of 07:58 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$249.65 +5.60 (+2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$249.94 +0.29 (+0.11%)

As of 07:49 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Revolution Medicines NASDAQ:RVMD

$190.27 +1.55 (+0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$188.25 -2.02 (-1.06%)

As of 07:57 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Spyre Therapeutics NASDAQ:SYRE

$98.96 -0.79 (-0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$98.96 0.00 (0.00%)

As of 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYRE, RVMD, BIIB, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYRE, RVMD, BIIB, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYRE, RVMD, BIIB, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, RVMD, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Revolution Medicines NASDAQ:RVMD

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYRE, RVMD, BIIB, and ALNY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYRE, RVMD, BIIB, and ALNY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYRE, RVMD, BIIB, and ALNY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, RVMD, BIIB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Revolution Medicines NASDAQ:RVMD

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools